Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 117

1.

Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial.

Winston DJ, Saliba F, Blumberg E, Abouljoud M, Garcia-Diaz JB, Goss JA, Clough L, Avery R, Limaye AP, Ericzon BG, Navasa M, Troisi RI, Chen H, Villano SA, Uknis ME; 1263-301 Clinical Study Group.

Am J Transplant. 2012 Nov;12(11):3021-30. doi: 10.1111/j.1600-6143.2012.04231.x. Epub 2012 Sep 4. Erratum in: Am J Transplant. 2013 Feb;13(2):529.

PMID:
22947426
[PubMed - indexed for MEDLINE]
Free Article
2.

Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study.

Winston DJ, Young JA, Pullarkat V, Papanicolaou GA, Vij R, Vance E, Alangaden GJ, Chemaly RF, Petersen F, Chao N, Klein J, Sprague K, Villano SA, Boeckh M.

Blood. 2008 Jun 1;111(11):5403-10. doi: 10.1182/blood-2007-11-121558. Epub 2008 Feb 19.

PMID:
18285548
[PubMed - indexed for MEDLINE]
Free Article
3.

Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.

Park JM, Lake KD, Arenas JD, Fontana RJ.

Liver Transpl. 2006 Jan;12(1):112-6. Erratum in: Liver Transpl. 2006 Mar;12(3):494.

PMID:
16382458
[PubMed - indexed for MEDLINE]
Free Article
4.

Cytomegalovirus infection after liver transplantation: current concepts and challenges.

Razonable RR.

World J Gastroenterol. 2008 Aug 21;14(31):4849-60. Review.

PMID:
18756591
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial.

Marty FM, Ljungman P, Papanicolaou GA, Winston DJ, Chemaly RF, Strasfeld L, Young JA, Rodriguez T, Maertens J, Schmitt M, Einsele H, Ferrant A, Lipton JH, Villano SA, Chen H, Boeckh M; Maribavir 1263-300 Clinical Study Group.

Lancet Infect Dis. 2011 Apr;11(4):284-92. doi: 10.1016/S1473-3099(11)70024-X. Epub 2011 Mar 21. Erratum in: Lancet Infect Dis. 2011 May;11(5):343.

PMID:
21414843
[PubMed - indexed for MEDLINE]
6.

Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients.

Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD; Valganciclovir Solid Organ Transplant Study Group.

Am J Transplant. 2004 Apr;4(4):611-20.

PMID:
15023154
[PubMed - indexed for MEDLINE]
Free Article
7.

A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.

Flechner SM, Avery RK, Fisher R, Mastroianni BA, Papajcik DA, O'Malley KJ, Goormastic M, Goldfarb DA, Modlin CS, Novick AC.

Transplantation. 1998 Dec 27;66(12):1682-8.

PMID:
9884259
[PubMed - indexed for MEDLINE]
8.

Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir.

Turgeon N, Fishman JA, Doran M, Basgoz N, Tolkoff-Rubin NE, Cosimi AB, Rubin RH.

Transpl Infect Dis. 2000 Mar;2(1):2-10.

PMID:
11429003
[PubMed - indexed for MEDLINE]
9.

High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial.

Singh N, Yu VL, Mieles L, Wagener MM, Miner RC, Gayowski T.

Ann Intern Med. 1994 Mar 1;120(5):375-81.

PMID:
8304654
[PubMed - indexed for MEDLINE]
10.

Maribavir: 1263W94, Benzimidavir, GW 1263, GW 1263W94, VP41263.

[No authors listed]

Drugs R D. 2007;8(3):188-92. Review.

PMID:
17472414
[PubMed - indexed for MEDLINE]
11.

Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.

Boeckh M, Bowden RA, Storer B, Chao NJ, Spielberger R, Tierney DK, Gallez-Hawkins G, Cunningham T, Blume KG, Levitt D, Zaia JA.

Biol Blood Marrow Transplant. 2001;7(6):343-51.

PMID:
11464977
[PubMed - indexed for MEDLINE]
12.

A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients.

Martin M, Mañez R, Linden P, Estores D, Torre-Cisneros J, Kusne S, Ondick L, Ptachcinski R, Irish W, Kisor D, et al.

Transplantation. 1994 Oct 15;58(7):779-85.

PMID:
7940710
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database.

Badley AD, Seaberg EC, Porayko MK, Wiesner RH, Keating MR, Wilhelm MP, Walker RC, Patel R, Marshall WF, DeBernardi M, Zetterman R, Steers JL, Paya CV.

Transplantation. 1997 Jul 15;64(1):66-73.

PMID:
9233703
[PubMed - indexed for MEDLINE]
14.

Maribavir: a novel antiviral agent with activity against cytomegalovirus.

Trofe J, Pote L, Wade E, Blumberg E, Bloom RD.

Ann Pharmacother. 2008 Oct;42(10):1447-57. doi: 10.1345/aph.1L065. Epub 2008 Aug 12. Review.

PMID:
18698013
[PubMed - indexed for MEDLINE]
15.

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

Gane E, Saliba F, Valdecasas GJ, O'Grady J, Pescovitz MD, Lyman S, Robinson CA.

Lancet. 1997 Dec 13;350(9093):1729-33. Erratum in: Lancet 1998 Feb 7;351(9100):454.

PMID:
9413463
[PubMed - indexed for MEDLINE]
17.
18.

Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.

Noble S, Faulds D.

Drugs. 1998 Jul;56(1):115-46. Review.

PMID:
9664203
[PubMed - indexed for MEDLINE]
19.

Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients.

Reischig T, Opatrný Jr K, Treska V, Mares J, Jindra P, Svecová M.

Kidney Blood Press Res. 2005;28(4):218-25. Epub 2005 Jul 21.

PMID:
16043964
[PubMed - indexed for MEDLINE]
20.

A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.

Reischig T, Opatrny K Jr, Bouda M, Treska V, Jindra P, Svecova M.

Transpl Int. 2002 Dec;15(12):615-22. Epub 2002 Nov 5.

PMID:
12478408
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk